PreveCeutical Medical Inc. PRVCF Archives - Page 3 of 6

TuesdayJul 24, 2018 11:08 am

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Launches Medicinal Cannabis Division

PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced the launch of a medicinal cannabis division, advancing PreveCeutical’s vision of becoming a global preventive healthcare company. The cannabis division’s responsibilities include bringing various high-quality, medicinal cannabis-based products to market and managing the company's nasal delivery Sol-gel research program as well as any resulting formulations. The cannabis division’s products will include transdermal patches, topical creams, capsules and other methods of administering medicinal cannabis. "The opening of the cannabis division at this crucial moment is very exciting and continues to move the company in an important direction. With Canada's upcoming…

MondayJul 16, 2018 3:01 pm

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Delivers Groundbreaking, Organic Options to Preventive Healthcare Market

PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) aims to be a leader in the preventive health sciences and provide revolutionary options for preventive and curative therapies utilizing organic products. An article discussing the company reads: “PreveCeutical currently has five research and development programs, including dual gene therapy for curative and prevention therapies for diabetes and obesity. The World Health Organization (WHO) states that some 425 million people around the world are living with diabetes, and that number is projected to rise to 629 million by 2045. Treating diabetes is a costly matter, both economically and in terms of physical…

MondayJul 16, 2018 12:48 pm

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) CEO Outlines Next Steps for Promising New Technologies

Company is targeting $3.8 trillion preventative medicine industry Sol-gel delivery system administers CBD-based medicines directly to the brain via nasal passages Company R&D includes anti-diabetes and obesity gene therapy and powerful non-addictive painkiller Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) expects to make promising progress in the research and development of a number of exciting products in 2018, according to the company’s chairman, CEO and President Stephen Van Deventer in an audio interview (http://ibn.fm/1SVjY). He explained that, while pharmaceutical and nutraceutical companies are well-established, there is a relatively untapped $3.8 trillion a year industry in preventative…

WednesdayJul 11, 2018 10:33 am

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Issues Update on Sol-gel Program

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning issued an updated on its soluble gel (“Sol-gel”) drug delivery research and development program, which involves testing an array of cannabis strains for the development and commercialization of cannabinoid-based Sol-gels. Per the update, the program uses five distinct Cannabis sativa L. strains containing an assortment of CBD:THC concentrations, enabling the development of medicinal cannabis products tailored for a broad range of ailments and diseases. The current focus of the Sol-gel program is on preparing formulations containing fixed CBD:THC concentrations that can be utilized with a custom…

ThursdayJul 05, 2018 3:07 pm

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Conducts Extensive Research on Sol-gel CBD-based Delivery System

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is presently working on the advancement of its Sol-gel drug delivery research program. An article discussing the company reads: “Currently, the company’s research is focused on testing various cannabis strains for the purpose of formulating potent and effective Sol-gels. PreveCeutical Chief Research Officer Dr. Harendra Parekh is leading the program. … In addition, various spray devices have already been tested. According to PreveCeutical CEO and President Stephen Van Deventer, a focus on safety regulations and a tamper-proof delivery system will be of paramount importance. While the Sol-gel program…

ThursdayJul 05, 2018 12:59 pm

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Targets Chronic Disease, Preventive Healthcare Market

Global preventive healthcare technologies and services market expected to reach $432 billion by 2024 Centers for Disease Control (CDC) states that seven out of 10 U.S. deaths are caused by chronic diseases such as diabetes, with global cost of treating diabetes reaching $776 billion within two decades World Health Organization recommended in December 2017 that cannabidiol (CBD) should not be scheduled as a controlled substance, citing its potential as a beneficial pharmaceutical PreveCeutical’s CBD-based Sol-gel delivery platform offers ease of application, better bioavailability and controlled cannabidiol release PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), headquartered in Vancouver, British…

TuesdayJul 03, 2018 11:32 am

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Continues Advancing Innovative Drug Delivery Research Program

PreveCeutical is continuing its extensive research work on the Sol-gel CBD-based delivery system An expansion to Australia has enabled the company to run simultaneous tests on cannabis strains and delivery systems The scientific work is in line with a growing demand for cannabidiol and medicinal cannabis products Over the past few months, PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) has been working on the advancement of its innovative Sol-gel drug delivery research program. The focus of the research is to apply Sol-gel technology to develop cannabinoid-based therapies for the relief of symptoms associated with pain, inflammation, seizures and…

FridayJun 29, 2018 12:41 pm

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Closes Oversubscribed Private Placement

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced the closing of its oversubscribed non-brokered private placement financing, which was previously detailed on April 9, 2018. Per the update, a total of 130,779,750 units were issued under the financing at a price of $0.05 per unit for total gross proceeds of more than $6.5 million. “I am very pleased to announce this oversubscribed placement due to investor demand in our financing and see this as a strong endorsement of the quality of our research programs and management team,” Stephen Van Deventer, chairman, CEO and…

ThursdayJun 28, 2018 11:48 am

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Develops Innovative Therapies as Alternative Medicine Market Surges

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is developing pioneering options for preventive and curative therapies by utilizing several creative pathways. An article further discussing the company reads: “Chronic diseases and recurring health care issues are taking an increasingly bigger piece of the economic pie and disrupting the lives of many millions of people. U.S. health care costs for chronic diseases totaled $1.1 trillion in 2016 and balloon to $3.7 trillion when lost economic productivity is calculated into the total economic impact. According to a new report by Grand View Research, people around the world, along with their…

MondayJun 25, 2018 12:59 pm

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Targets Debilitating Disorders with Novel CBD-based Drug Delivery Platform

Direct health care treatment for chronic health conditions totaled $1.1 trillion in 2016 Total economic impact of $3.7 trillion in health care costs for chronic diseases in U.S. equivalent to nearly 20 percent of the U.S. gross domestic product Medical research into CBD-based therapies to treat epilepsy and other neuropsychiatric disorders holds great promise for affected individuals Development of CBD-based drug delivery platform that’s able to cross blood brain barrier via nasal route Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is developing innovative options for preventive and curative therapies using some of nature’s most compelling…

Site Search

Company Search

Tag: PreveCeutical Medical Inc. PRVCF